Intestinal Cancer
Conditions
Brief summary
Studies that have investigated different bowel preparations in patients with history of colorectal surgery are surprisingly lacking.Therefore, which is the best colon preparation in this subgroup of patients is still unknown. Polyethylene glycol (PEG)-based solutions are the most popular and safest bowel preparation regimens, however the 4-Liter volume is often poorly tolerated. More recently, it has been shown that the use of a low volume preparation (2-Liter PEG solution with the adjunct of a laxative, bisacodyl) achieves comparable bowel cleanliness rates to 4-Liter PEG in general population.The primary aim will be to compare the efficacy of 2-L mixed preparation (bisacodyl plus PEG) to 4-L PEG preparation.
Interventions
DRUGPolyethylene glycol
DRUGBisacodyl
Sponsors
Ospedale Santa Maria delle Croci
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Outpatients 2. ≥18 yrs old, 3. Prior history of colorectal resection due to colo-rectal cancer, referred for surveillance colonoscopy
Exclusion criteria
1. Inpatients 2. Emergency Colonoscopy 3. Comorbidities: Congestive heart failure, history of kidney disease, history of solid organ transplant 4. Pregnant and/or lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| quality of bowel preparation rated according to a modified Ottawa bowel preparation scale | about 2 weeks after the randomization |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Tolerability to the preparation (specific questionaire) | participants will be followed from the randomization until the time of colonoscopy, about 2 weeks after the randomization | Tolerability will be assessed by using a questionnaire completed by the patients on arrival at the endoscopy unit before colonoscopy. The patient acceptance/satisfaction to bowel preparation will be evaluated with the following question: What is the extent of your disturbance due to bowel preparation? Severe (the bowel preparation assumption was stopped and not completed)(score 3) Moderate (bowel preparation assumption was stopped several times because of side effects but finally completed)(score 2) Mild (bowel preparation was completed without pauses but with some mild side effects)(score 1) No side effects (score 0) |
| safety (adverse event rate) | participants will be followed from the randomization until the time of colonoscopy, about 2 weeks after the randomization | Safety will be evaluated through reported adverse events, physical examination and vital signs |
| Lesion detection (type and lesion detection rate/patient) | about 2 weeks from the randomization | Polyps will be categorized as non-neoplastic or neoplastic (ie, adenomatous). Adenoma will be diagnosed by pathological evaluation of retrieved polyps. Adenomas will be considered advanced when they will be ≥10 mm in size, with villous architecture, high-grade dysplasia or intramucosal carcinoma (pTis), or 3 or more adenomas will be found. Invasive cancer will be considered when malignant cells will be observed beyond the muscularis mucosa. Size of adenoma will be obtained from both the colonoscopist's assessment and the pathology report, with the larger measurement being used in the analyses. Site of adenoma will be recorded by the colonoscopist at the time of polypectomy. Lesions at or proximal to the splenic flexure will be termed right-sided lesions, those distal to the splenic flexure as left-sided, taking into account the type of colorectal surgical resection underwent by the patient. The adenoma detection rate will be defined as the proportion of colonoscopies with adenomas. |
Countries
Italy
Outcome results
None listed